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Abstract
Background: Gene-set enrichment analyses (GEA or GSEA) are commonly used for biological characterization of an
experimental gene-set. This is done by ﬁnding known functional categories, such as pathways or Gene Ontology
terms, that are over-represented in the experimental set; the assessment is based on an overlap statistic. Rich
biological information in terms of gene interaction network is now widely available, but this topological information is
not used by GEA, so there is a need for methods that exploit this type of information in high-throughput data analysis.
Results: We developed a method of network enrichment analysis (NEA) that extends the overlap statistic in GEA to
network links between genes in the experimental set and those in the functional categories. For the crucial step in
statistical inference, we developed a fast network randomization algorithm in order to obtain the distribution of any
network statistic under the null hypothesis of no association between an experimental gene-set and a functional
category. We illustrate the NEA method using gene and protein expression data from a lung cancer study.
Conclusions: The results indicate that the NEA method is more powerful than the traditional GEA, primarily because
the relationships between gene sets were more strongly captured by network connectivity rather than by simple
overlaps.
Background
Gene-set enrichment analyses (GEA or GSEA) [1-3] are
commonly used to characterize experimentally derived
alteredgenesets(AGSs).The‘alteration’isassociatedwith
a certain biological state, such as a cell culture pertur-
bation or a malignant tumor. (Later we will distinguish
GEA from GSEA, but to avoid repetitiveness in this Intro-
duction we will use GEA as a generic concept. Since
there are many frequently-used acronyms in this paper,
we tabulate them in Table 1.) A typical AGS is a list of
diﬀerentially expressed (DE) genes, and GEA identiﬁes
which previously known functional gene sets (FGSs) are
over-represented in AGSs. Although this is both infor-
mative and intuitively clear, the majority of genes have
notbeenassignedtoanybiologicallyinformativecategory,
i.e. a Gene Ontology (GO) term or a pathway. The sen-
sitivity of these analyses is limited by the AGS size, but
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expanding the set to include low-ranked genes (e.g. less
diﬀerentially expressed) is not always biologically mean-
ingful. Moreover, the experimental platform suggesting
the AGS (e.g. gene expression array) might be biologically
disjoint from the major mechanisms of activity in the FGS
(e.g., mutation or protein phosphorylation).
In parallel with the development of GEA and expression
measurement technology, biological knowledge about
gene and protein interaction is also growing rapidly. Gene
networks readily connect well- and poorly annotated pro-
teins, and combine various biological mechanisms. A few
examples of current applications include: inference con-
cerning the functions of previously unannotated genes
[4], extension of GO terms and pathways [5], ﬁnding
novel disease genes [6] and prioritization of disease gene
candidates [7].
There are currently a number of network-based meth-
ods that characterize gene sets rather than individual
g e n es.S i m i la r l yt oG EA,so m em et h odsca nbec o n s i d e r ed
network enrichment analysis (NEA). Such approaches
have revealed network patterns that are enriched com-
pared to those expected by chance. For example, using
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Table 1 List of acronyms and their meanings
Acronym Full word Brief description
AGS Altered gene set A list of diﬀerentially expressed genes in experiment
FGS Functional gene set A list of genes that were previously known to be related
GEA Gene enrichment analysis A method of counting overlaps between AGS and FGS
GSEA Gene set enrichment analysis A method using the maximum overlap between AGS and FGS
NEA Network enrichment analysis A method of measuring network connectivity between AGS and FGS
FNEA Fixed network enrichment analysis A NEA method when AGS is a list of k top-ranking genes
MNEA Maximum network enrichment analysis A NEA method to avoid dependence on k
an information-theoretic method, Huttenhower et al. [8]
analytically derived scores to quantify network relations
between distinct biological processes from GO terms.
Shojaie and Michailidis [9] suggested a linear model
approach within an orthogonal microarray design and
employed both the gene expression data and a previously
known gene network to detect GO terms most inﬂu-
ential in the transcriptome perturbation. Unfortunately,
this method would require extensive modiﬁcation and
statistical analyses for every new application.
The existing network-based methods have not fully
integrated the topological information in the gene net-
work and the functional information about biological
processes. JActiveModules [10] is a popular and easy to
use software, as it is run on the state-of-the-art net-
work browser platform Cytoscape [11]. The idea is to
ﬁnd modules in the global network based on the signif-
icance of gene alteration (usually diﬀerential-expression
p-values). Note here that these modules are not biologi-
cally characterized by any known FGS. A similar method
was suggested in Liu at al. [12], using their own soft-
ware. As in JActiveModules, network modules enriched
in DE genes are ﬁrst identiﬁed, and these modules serve
as the AGSs. The biological characterization of the iden-
tiﬁed modules proceeds in the same way as GEA: known
FGSs are assessed for being over-represented in the AGSs
using Fisher’s exact tests. Hence, the network topology
inﬂuences the formation of AGS, but not the relation-
ships between AGS and FGS. Another similar approach
was implemented in the Ingenuity Pathway Analysis soft-
ware (IPA; http://www.ingenuity.com). Lists of diﬀeren-
tially expressed [13] or alternatively spliced genes [14]
were found to be associated with certain biological pro-
cesses within limited ‘gene networks’ (using IPA terminol-
ogy). To our knowledge, none of the methods developed
so far oﬀers a straightforward and transparent interpreta-
tion comparable to GEA. Such a method should exploit
the topological properties of the networks, in particular
the interactions between the AGS and FGS, and should
provide a proper statistical inference.
In this paper we present a method of network enrich-
ment analysis that systematically implements the network
approach to describe novel gene sets with biologically
meaningful functional categories. The method integrates
two kinds of biological information: functional informa-
tion (currently available for a minority of genes) and
network connectivity of nearly all protein-coding genes.
In contrast to traditional GEA, our NEA method quanti-
ﬁes the over/under-representation of the functional group
members among the neighbors in the gene network rather
than in the AGS itself. For statistical inference, we devel-
oped a fast network randomization algorithm in order
to obtain the distribution of any network statistic under
the null hypothesis of no association between an AGS
and FGS. We demonstrate applications of NEA on high-
throughput gene and protein expression datasets from
a lung cancer study, and compare its performance and
power with those of GEA. We provide an R package called
‘nea’, freely available at http:/www.meb.ki.se/∼yudpaw.
For pedagogic purposes, in Section C of the Additional
ﬁle 1, we also provide a fully worked-out example of
analysis of lung cancer data from Bild et al.’s [15].
Methods
Data from a lung cancer study
For illustration we used expression data from a cohort
of 123 lung cancer patients who underwent complete
surgical resection at the Institut Mutualiste Montsouris
(Paris, France) between 30 January 2002 and 26 June
2006. The recruitment of participants was carried out
in compliance with the Helsinki Declaration, and this
study was approved by the ethics committee of the Insti-
tut Gustave Roussy (Paris). All involved patients gave a
written informed consent. From each patient, snap-frozen
tumor and corresponding normal tissues were collected.
We assayed the samples for gene expression, performed
using dual-color human array from Agilent containing
41,000 gene probes; a dye-swap was employed for each
sample and the log-ratio value was combined by averag-
ing. Scanned microarray images were analyzed by using
Agilent Feature Extraction software version 10.5.1.1. A
loess normalization was then performed using the nor-
malizeWithinArrays function from R package limma [16].Alexeyenko etal. BMCBioinformatics 2012, 13:226 Page 3 of 11
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For a subset of 16 tumor samples we also obtained
protein expression proﬁles. From each sample 160 μg
of protein was taken oﬀ and precipitated using four
volumes of ice cold acetone. The precipitated samples
were dissolved in iTRAQ dissolution buﬀer and digested
according to manufacturers instructions (Applied Biosys-
tems). Three proteomics platforms were used: Applied
Biosystems’s MALDI TOF-TOF, Agilent’s Accurate-Mass
Q-TOF and a hybrid LTQ-Orbitrap from Thermo Fischer
Scientiﬁc. From these platforms, a total of 4,406 proteins
were detected in at least one sample.
Altered gene sets
AGSs are usually deﬁned as genes that are diﬀerentially
expressed (DE) between clinical groups. In our current
application we deﬁned the AGS as the DE genes in the
within-person comparison of tumor vs normal tissues, so
each sample (patient) had an associated AGS. The top-
ranking genes are not interpreted statistically signiﬁcant
DE genes, but as potentially deregulated genes. To investi-
gate the functional heterogeneity of individual tumors, we
ranked the diﬀerences between individuals. To this end,
we transformed the mRNA expression data to diﬀerence
values that conveyed how uncommon is the diﬀerential
expression of gene g in patient p compared to the group of
patients:
log(T/N)pg − ave(log(T/N)).g,( 1 )
where log(T/N) is the log intensity-ratio of tumor vs
normal expression. For the AGS with a ﬁxed size, we
considered the top 100 (k = 100) genes per individual.
The AGS from the protein expression data was deﬁned
similarly: for each sample we kept proteins whose expres-
sion exceeded the corresponding average across 16 sam-
ples. The number of proteins in the AGSs has a median of
424 (range 257 to 654).
NEA statistics and randomization
LetA(k) beanAGSofsizek,and deﬁnenAF(k),am eas u r e
of network connectivity between A(k) and a known FGS
(F) ,a st h en u m b e ro fl i n k sb e t w e e nm e m b e r so fA(k) and
F. In practice we might be interested to see the network
connectivity for a ﬁxed number k of top-ranking genes.
Since the connectivity depends on the constituent genes,
we correct nAF(k) by its expected value:
dAF(k) = nAF(k) − μAF(k)
where μAF(k) is the expected number of links between
A(k) and F. The computation of μAF(k) is performed
using the network randomization described below. To
avoid dependence on k,w ed e ﬁ n et h el a r g e s t( s i g n e d )
deviation between nAF(k) and its expected value:
dmax = max
k
{nAF(k) − μAF(k)}
dmin = min
k
{nAF(k) − μAF(k)}
dAF =

dmax,i fdmax ≥− dmin
dmin,i fdmin ≤− dmax.
The immediate statistical question is whether an
observed dAF(k) or dAF is signiﬁcantly higher or lower
than expected under the null hypothesis of no biologi-
cal relation. This assessment is not trivial, as we need to
respect the network topology. Crucially, it is not adequate
to compare the AGS with a random list of genes. The
scale-free property of most biological networks means
that the degree distribution is highly skewed, with a few
network hubs but a large number of sparsely connected
nodes. (The degree of a node is deﬁned as the number of
neighbors connected to that node). Randomly replacing a
network hub by a sparsely connected gene does not make
sense. A hub gene may have a few links to genes in a FGS
simply by chance, whereas for a non-hub gene the same
number of links would indicate an important biological
pattern.
In some simple cases, analytical calculations of the null
distribution are possible, for example using the hyper-
geometric distribution [17]. However, for general net-
works, e.g. when gene groups may share members, the-
oretical analyses are not feasible. In such a situation, for
example, Li et al. [18] chose to limit their analysis to only
cases where the gene groups did not overlap, which is a
serious limitation.
A general approach in generating the null distribution
of the network statistic is based on a network randomiza-
tion that preserved the degree distribution. This approach
was applied, for example, by [19-22]. The basic algorithm
rewires the whole network by systematic swapping of net-
work links so that the degree of each node is preserved,
while its network neighbors are replaced. The algorithm is
as follows:
• Step0:Randomlyselectapairofedges(A-BandC-D).
• Step 1: ‘Rewire’ the two edges in such a way that A
becomes connected to D, while B connects to C. In
case one or both of these new links already exist in
the network, this step is aborted and a new pair of
edges is selected.
Repeated applications of the above steps lead to a ran-
domized version of the original networks. However, for
a large network it is not clear at what point a suﬃcient
level of rewiring has been achieved, and the algorithm is
also ineﬃcient as it rejects too many rewired links that are
generated earlier.Alexeyenko etal. BMCBioinformatics 2012, 13:226 Page 4 of 11
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The key to a fast and transparent algorithm is to ﬁrst
representthenetworkintermsofabinaryadjacencytable,
with each node represented by a row and a column, and
the cell entry ‘1’ represents connected nodes, and ‘0’ oth-
erwise. The table is symmetric, and its margin is equal
to the degree distribution of the nodes. Thus our goal is
to generate a randomized table with ﬁxed margins, simi-
lar to the hypergeometric sampling model associated with
the Fisher’s exact test, but with the additional constraints
of symmetry and binary entries. Adapting the hypergeo-
metric sampling model to these constraints, the network
randomization is achieved by the following sequential
algorithm:
• Step 0: Start with a list of nodes 1,...,N, ordered by
degree δ1 ≥···≥δN > 0.
• Step 1: Assign the δ1 links of the largest node to the
other nodes randomly but with probability weighted
by δ2,...,δN.
• Step 2: Remove node 1, and reduce by 1 the degree of
each node connected to node 1.
• Step 3: Construct a new list of remaining nodes with
positive degrees, then reorder and renumber them
1,...,N, and go to Step 1. Stop if there is no
remaining node with positive degree.
At ﬁrst appearance the use of the weights (δ2,···,δN)
makes it more diﬃcult to understand the distributional
property of generated networks. Here we explain why
the weights lead to an unbiased random sample of net-
works with a given degree distribution. First consider a
naive algorithm for generating networks uniformly from
all networks with the given degree distribution:
1. Construct a random network: for i = 1,···,N,t a k e
δi nodes randomly with equal weights as neighbors of
the ith node. The choices of neighbors are made
independently across diﬀerent nodes.
2. Test the network: compute the resulting degree
distribution and accept the network if it has the
required degree distribution, otherwise reject it.
Since a great majority of generated networks will not
satisfy the given degree distribution, and will thus be
rejected, this algorithm is highly ineﬃcient. However,
clearly the accepted/generated networks are uniformly
distributed over all networks with the given degree dis-
tribution. Now, at Step 1 the probability that the second
largest node has a link with the largest node is
N−2
δ2−1

N−1
δ2
 =
δ2
N − 1
Likewise, the probability that the node with degree δi
has a link with the largest node is δi
N−1. This is exactly the
same as the weights in our algorithm. Thus, our weighting
scheme simply oﬀers a short-cut to produce truly unbi-
ased random networks. A similar proof was used in [23].
Our proposed algorithm is computationally very eﬃcient,
sinceeachnodeneedstobevisitedatmostonce.Theaver-
a g en u m b e ro fn o d e st h a tn e e dt ob ev i s i t e dd e p e n d so n
the degree distribution. In our application with ∼16,000
nodes and ∼1.5 M links (see the subsection on gene net-
work below), this average was ∼8,200 nodes. On a 3
GhZ PC with 4 Gb RAM, using native R commands, the
algorithm takes ∼60 seconds.
Denote by n∗
AF(k) the number of links between A(k)
and F based on the randomized network. On replicating
the randomization many times (in practice we used 100
replications), we obtain of collection of n∗
AF(k)’s, which
behave as a random sample from the null distribution. We
c a nt h e ne s t i m a t eμAF(k) by the average of n∗
AF(k) over
the randomizations, and compute d∗
AF(k) and d∗
AF based
on the randomized network, and compute the right-sided
p-value as the proportion of d∗
AF’s ≥ dAF (similarly the
left-sidedp-value).Theone-sidedp-valueistheminimum
of these two, and the two-sided p-value is twice the one-
sided p-value. We checked that the p-values computed for
d∗
AF for a typical FGS (with median size), across all AGSs
and all the randomized networks, followed a uniform dis-
tribution, indicating that the randomization worked as
expected; see Figure 1.
For easy comparison with other methods we computed
the maximum NEA (MNEA) score as
z =
dAF − ¯ dAF
sAF
,
Figure 1 The distribution of the p-values of the statistics
computed from the randomized network. If the randomization
works well, then the distribution should be uniform.Alexeyenko etal. BMCBioinformatics 2012, 13:226 Page 5 of 11
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where ¯ dAF and sAF are the mean and standard deviation of
d∗
AF. Similarly, the ﬁxed NEA (FNEA) score is computed
as
z(k) =
dAF(k) − ¯ dAF(k)
sAF(k)
,
where ¯ dAF(k) and sAF(k) are the mean and standard
deviation of d∗
AF(k). We use the term NEA when refer-
ring to both FNEA and MNEA. These scores can be
used as a measure of activation of the FGS, thus pro-
viding a biological characterization of the AGS. Assum-
ing a normal distribution, one could convert the scores
to p-values, which are convenient for combining results
of network analyses with information from other ﬁnd-
ings,suchasgenome-wideassociationstudies,small-scale
experiments, mutation analysis, etc.
To assess a large number of AGS-FGS pairs, we trans-
form the p-values into false discovery rates (FDR) [24].
Let p1,...,pm be the ordered p-values from m AGS-FGS
pairs. The standard estimate of FDR as a function of the
p-values is given by
FDR(pk) = mˆ π0pk/k,
where ˆ π0 is the estimated proportion of null results.
Monotonicity is then imposed by taking the cumulative
minimum over all p-values ≥ pk.
Comparative procedures: GEA and GSEA
For comparisons with NEA, the GEA score was computed
from an AGS of size k as follows. Firstly, a standard 2×2
table is constructed for each AGS-FGS pair according to
whether or not a gene belongs to the AGS and FGS. In
small samples the Fisher’s exact p-value is usually com-
puted using the hyper-geometric distribution, which, as
explained above, is equivalent to randomizing the genes
while ﬁxing the marginal totals. Liu et al. [12] used this
assessment for their statistic, which is why the method
was more like a GEA rather than a true NEA, as it ignored
thenetworktopologyinitsinference.Forconvenienceand
easy comparison with NEA scores, we compute a GEA
score as
zk =
log(ad/bc)
(1/a + 1/b + 1/c + 1/d)1/2,
where (a,b,c,d) are the table frequencies. This can be
seen as the z-statistic associated with the log odds-ratio.
If some observations in the table are zero, then they are
replaced with 0.5 to prevent z from being undeﬁned.
Similar to MNEA, the gene-set enrichment analy-
sis (GSEA) avoids the dependence on k by taking the
maximum deviation from zero encountered in a running
sum statistic [1]. GSEA enrichment score is deﬁned as
max
i



 


gj∈FGS,j≤i
1
NAGS

FGS
−

gj ∈FGS,j≤i
1
NAGS − NFGS



 

,
where gj is the jth-ranked gene in the AGS, NR is the num-
ber of genes in R. As with the GEA, however, GSEA also
does not use any network topology in its inference. To
assess the signiﬁcance of observed enrichment score, a
permutation test procedure was originally developed for
group comparisons. In our application the AGS is deﬁned
for each person, so the permutation is performed within
each person.
Gene network
We compiled a comprehensive network by merging 4
networks: (1) the data integration network of func-
tional coupling [21], re-generated with updated datasets
on protein-protein interactions (IntAct), gene expression
(GEO) and sub-cellular localization (GO). This network
contains 1,515,318 links, with each gene identiﬁed by
the ENSEMBL gene ID; (2) curated pathways (KEGG
KGML ﬁles, as of June 2010), consisting of 25,765 links;
(3) known protein complexes (KEGG and CORUM, as of
June 2010), consisting of 54,046 links; (4) coherent anno-
tations (coherence was estimated by a custom software as
simultaneous presence of two genes in a series of overlap-
ping GO terms, weighted for compactness of the latter),
consisting of 20,412 links.
The ﬁnal network contained 1,445,027 functional
links between 16,299 distinct HUPO genes (some links
were lost as we translated the ENSEMBL IDs to
HUPO gene symbols). Note that no evidence from
the lung cancer datasets was involved in the net-
work construction. The network is available from
http://www.meb.ki.se/∼yudpaw.
Functional gene sets
To characterize AGSs by involvement of known biolog-
ical processes, we compiled a list of genes which are of
importance in cancer:
• All 235 pathways in the KEGG database (as of 21 Apr.
2010);
• 16 GO terms that could be related to hallmarks of
cancer [25];
• 7 cancer-related pathways and otherwise deﬁned FGS
from publications reporting on large-scale cancer
genome projects;
• EMT, epithelial-mesenchymal transition (a pathway
behind metastatic development, manual curation by
S. Souchelnytskyi);Alexeyenko etal. BMCBioinformatics 2012, 13:226 Page 6 of 11
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• Acidic switch (a pathway behind tumor-speciﬁc
pH-shift, i.e. tumor’s ability to grow in hypoxic
environment, manual curation by A. de Milito).
In total the list included 5,698 distinct HUPO gene sym-
bols assigned to 264 FGSs (overlaps are allowed). The list
of pathways with their meanings and references are given
in Section B of the Additional ﬁle 1 Report. The complete
list of genes for each FGS is available as an RData ﬁle at
http:/www.meb.ki.se/∼yudpaw.
Result and discussion
Simple illustration
Theprincipleofthenetworkenrichmentanalysisisshown
in Figure 2. Panel A shows a schematic diagram: in
order to characterize an experimentally derived AGS with
Figure 2 A schematic diagram of counting network links and a real example of network links. (A) A simple example of how links are counted
betweengenesinAGSandFGS.The’x’symbolindicatesaﬁxednumberk ofgenes;(B)Arealisticexampleofnetworklinksbetween257deregulated
proteins in a tumor (diamonds) and 10 genes known to be involved in the epithelial-mesenchymal transition (circles). Network nodes without links
to the AGS or FGS genes are not shown. The graph is generated using a graphics tool in the FunCoup web site (http://funcoup.sbc.su.se).Alexeyenko etal. BMCBioinformatics 2012, 13:226 Page 7 of 11
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relationships to an FGS, we count the number of links
between members of the two sets as given by a known
background network. In this ﬁgure there are 8 links.
Allowing such links expands the potential biological char-
acterization of the altered genes using rich information
on gene interaction networks. Panel B shows a realis-
tic example from the smallest AGS from the lung-cancer
proteomicsdata:theAGSconsistsof257deregulatedpro-
teins in one lung tumor sample (diamonds). The FGS con-
tains 10 genes involved in epithelial-mesenchymal tran-
sition (EMT), namely TWIST1, SNAI1, SNAI2, SNAI3,
S I P 1 ,C D H 1 ,C D H 2 ,V I M ,F N 1 ,A C T A 2 .I nt o t a l ,8 8l i n k s
were found between the AGS and FGS. Note that overlaps
between AGS and FGS are allowed, and in fact these over-
l a p st e n dt op r o d u c em a n yl i n k s ;i nc o n t r a s t ,i nG E At h e
enrichment is based on the number of such overlaps only.
To assess the level of connectivity, we generated a series
of randomized networks that preserved the degree dis-
tribution of all genes. The estimated number of links
expected by chance was 51.6 and the FNEA z-score was
4.97. In the other 15 patients with proteomics data, the
z-score associated with EMT ranged from 1.81 to 9.83, so
that the current sample was ranked 6 out of 16. In total, 15
z-scores out of 16 exceeded 1.96. Importantly, two of the
EMT proteins, VIM and FN1, were themselves found in
eight and ten sample AGSs, respectively. As a result, GEA
alsodetectedsomerelationshipbetweenthesetumorsand
EMT,butonly6oftheGEAscoresexceeded1.96.Looking
at Figure 2B explains the higher sensitivity of NEA: net-
work connections lead to ACTA2, CDH1, SIP1, and other
EMT genes that were themselves not found in the AGS. In
addition, FN1 and VIM contributed with many links.
Performance on known gene-sets
To demonstrate the biological validity of NEA, we ana-
lyzed gene sets altered in our lung cancer dataset versus
known gene groups relevant to this disease. For each sam-
ple, we set the AGS to be the top 100 genes DE between
tumor and normal tissues, so we had a total of 123 AGSs.
Ding et al. [26] compiled a comprehensive list of 623
genes – known tumor suppressors, growth factors etc. –
and screened them for somatic mutations in lung adeno-
carcinoma tissues. Among the 623 genes, 26 genes were
declared ‘conﬁdent’ drivers in the sense that they are
mutated at signiﬁcantly high frequency. We performed
NEA on (i) the full set of 623 genes, (ii) the set of 26 con-
ﬁdent driver genes, and (iii) the set of 153 genes for which
there were at most one mutation was detected by [26].
Another functional group was the pathway of non-small
cell lung cancer from KEGG database.
Additionally, we downloaded a list of genes somatically
mutated in lung cancers from the COSMIC database [27],
which is potentially less biased towards previously known
cancer drivers. The list of 764 genes not included in Ding
et al. [26] was split into two parts: (i) 110 genes that
mutated more than once and (ii) 654 genes reported only
once. The latter can be regarded as a negative control.
To get an unbiased comparison, we took 50 randomly
sampled sets consisting of 110 genes from the 654 genes.
The latter lists were expected to contain many spuriously
reported passenger genes, so we expect fewer links to our
lung cancer AGSs.
The results are summarized in Table 2. If the 623 genes
from [26] were involved in lung cancer, then we should
e x p e c ts o m ee n r i c h m e n ti nl i n k st oo u rA G S s .I n d e e d ,
according to MNEA, 114 out of 123 individual AGSs had
nominally signiﬁcant enrichment score (z-score > 1.96).
Hence, the original full set indeed contained many genes
involved in lung cancer, irrespective of their vulnerability
t om u t a t i o n s .F o rM N E A ,ac o m p a r a b l en u m b e ro fi n d i -
vidual AGSs (95 and 102) were enriched in the subset of
drivergenesandrarely mutatedgenes.However,using the
top 100 genes (FNEA), we observed a higher number of
signiﬁcant AGSs for the driver subset compared to the full
set, while the rarely mutated subset had the fewest. Thus,
FNEA showed higher speciﬁcity than MNEA for distin-
guishing driver genes. Finally, FNEA and MNEA showed
48and99AGSsthatwerelinkedtothenon-smallcelllung
cancer pathway, respectively (KEGG05223 in the Table).
As for the COSMIC gene sets, even the set of multi-
plemutationshadlowernumbersofsigniﬁcantAGSsthan
the above results. Also, using FNEA, we could separate
those genes that mutated once from those with more than
1 mutation, again potentially distinguishing the sets of
passenger and driver mutations.
In general GEA detected only a few individuals with
activated cancer pathways; see Table 2. For example, only
1 of the 123 individuals had signiﬁcant enrichment of 623
cancer genes of [26], and 2 in the non-small cell lung
cancer pathway. GSEA showed higher overall sensitivity
compared to GEA, but GSEA appeared to be less sensitive
than NEA. For example, for 26 driver genes of [26] it only
identiﬁed 16 signiﬁcant individuals, compared to 74 and
95 for FNEA and MNEA, respectively.
Among the most activated pathways according to GEA,
we saw benzoate degradation via hydroxylation, high-
mannose type N-glycan biosynthesis, biotin metabolism,
lysine biosynthesis and lipoic acid metabolism. How-
ever, according to the NEA scores, few individuals were
activated in these pathways. Thus, many pathways not
known to be activated in cancer were found to be sig-
niﬁcant in all individuals by GEA, but not by NEA. On
the other hand, putative cancer-related pathways, such
as response to hypoxia, pathways in cancer, angiogenesis
and the MAPK signaling pathway, were activated in most
individuals according to NEA, but not according to GEA.
The results indicated that NEA can detect transcrip-
tomic activity of cancer drivers via functional relations inAlexeyenko etal. BMCBioinformatics 2012, 13:226 Page 8 of 11
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Table 2 Network enrichment analysis of lung cancer-related gene sets to patient-speciﬁc altered gene sets
Functional gene set FNEA (k = 100) MNEA GEA (k = 100) GSEA
Ding et al., 2008
All (623 genes) 66 114 1 102
Drivers (26) 74 95 21 16
Mutated ≤ 1 (153) 39 102 2 75
COSMIC
Detected > 1 (110) 34 33 22 30
Detected once (median)∗ (110) 18 52 9 28.5
KEGG05223 non-small cell lung cancer (56) 48 99 2 40
Largest contrast GEA > FNEA
KEGG00362 Benzoate degradation via hydroxylation (3) 4 27 123 31
KEGG00513 High-mannose type N-glycan biosynthesis (4) 2 5 123 24
KEGG00780 Biotin metabolism (4) 1 13 123 11
KEGG00300 Lysine biosynthesis (5) 0 6 123 34
KEGG00785 Lipoic acid metabolism (4) 0 2 123 18
Largest contrast FNEA > GEA
GO0001666 Response to hypoxia (163) 119 114 11 105
KEGG05200 Pathways in cancer (254) 112 118 6 99
GO0001525 Angiogenesis (129) 115 113 10 118
KEGG04010 MAPK signaling pathway (286) 107 114 4 82
KEGG04020 Calcium signaling pathway (183) 99 108 5 60
KEGG05223 is non-small cell lung cancer pathway. ‘COSMIC’ genes include the lung-cancer somatic mutations in the COSMIC database, but exclude those in [26].
∗ indicates the median from 50 randomly sampled sets.
the network, whereas the mutated genes themselves are
not known directly. The fact that both frequently mutated
genes (26 genes) and rarely mutated genes (most of the
other FGSs) scored high suggests that the NEA is poten-
tially more powerful than the mutation frequency analysis
[26]. Furthermore, NEA enables investigation at the level
of individuals rather than on pooled observations. Indeed,
a large number of cancer drivers could not be detected
by Ding et al. [26] or other studies due to low mutation
frequency observed in the samples.
We further compared the procedures in terms of the
false discovery rates (FDR): a better procedure should
produce smaller FDR. Thus we analysed 123 individual
AGSswiththe264FGSsasdescribedpreviously.Figure3a
and 3b show the average FDR curves obtained from indi-
vidualAGSs.SinceFNEAandGEAusedaﬁxednumberof
top k genes,whileMNEAandGSEAusedthelargestdevi-
ation over k, separate comparisons were made to compare
like with like. Figure 3a indicates that for the top rank-
ing AGS-FGS pairs, FNEA had lower FDR than GEA.
Likewise, Figure 3b shows that MNEA had lower FDR
than GSEA.
We also compared z-score distributions from GEA to
those from MNEA and FNEA (Additional ﬁle 1: Figure
Figure 3 Average of estimated FDRs versus the number of AGS-FGS pairs that are declared signiﬁcant. (a) FNEA (solid) versus GEA (dashed)
(b) MNEA (solid) and GSEA (dashed). The average values were calculated over 123 individuals.Alexeyenko etal. BMCBioinformatics 2012, 13:226 Page 9 of 11
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S1).In general, there was little correlation between GEA
a n dN E As c o r e s ,w h i c hw o u l db ee x p e c t e da st h e ya r e
based on diﬀerent information. In most situations NEA
could achieve higher ranges of scores because there are
more ways a gene can interact with other genes in a path-
way than simply by being an overlap. On the other hand,
the correlation between FNEA and MNEA was 0.65; since
FNEA is much simpler to compute than MNEA, in prac-
tice FNEA could be suﬃcient for capturing the network
enrichment.
Factor analysis
Once constructed, the NEA scores from each individ-
ual can be used for further analyses. For illustration we
employed factor analysis [28] in order to explore the lower
dimensional space that characterized molecular proﬁles
of individual patients. The varimax rotation algorithm is
used because it often provides meaningful interpretations
for the factor loadings for each variable (FGS). The indi-
vidual NEA scores of FGSs served as input variables in
the factor analysis. In order to make the results more
interpretable, the analysis was performed separately for
the following three groups of pathways: (a) cancer-related
pathways; (b) signaling and cancer-related pathways; and
(c)metabolicpathways.ThesearegiveninSectionBofthe
Additional ﬁle 1 Report.
First the mean and variance of FGS scores are given
in Figure S2 of the Additional ﬁle 1 Report. The cancer-
related pathways were neither the most enriched nor
the most variable. Many other signaling KEGG pathways
exceeded them in terms of these measures. The metabolic
pathways seemed as variable across individuals as sig-
naling ones. Looking at metabolic pathways most highly
correlated to signaling pathways and cancer hallmarks,
we found that these correlations occurred when the same
enzymeswereassignedtobothametabolicandasignaling
pathway. For example, the RNA-speciﬁc adenosine deam-
inase ADAR (atrazine degradation, KEGG00710) was
related to (but not a member of) the cell cycle pathway
(KEGG04110) due to its molecular function. Similarly,
protein phosphatases that enable biological signaling (and
hence belong to multiple signaling pathways) are clas-
siﬁed as enzymes of the inositol phosphate metabolism
(KEGG00562).
Cancer-relatedpathways
We used 16 FGSs that are the known hallmarks of can-
cer [25] and 13 processes relevant to tumor growth. The
factor loadings revealed that variability of transcription
is mostly shaped by Factor 1: PDGF, IGF, and TGF-beta
signaling, angiogenesis and epithelial-mesenchymal tran-
sition (EMT), Factor 2: apoptosis and ErbB (also known
as HER2 or EGFR) signaling, Factor 3: p53 signaling and
cell cycle. We found that EMT was signiﬁcantly enriched
in the virtually all tumors (FNEA z score ranged from 2 to
30), so the variability across patients reﬂects the varying
degree of activation. On the other hand, p53 signaling and
cell cycle were signiﬁcantly (z > 2) activated in subsets of
individuals(79and24outof123individuals,respectively).
Signalingpathways
To reveal how cancer-related pathways interact with the
normal signaling machinery, we studied factor structure
of the combined cancer-related pathways and 55 sig-
naling pathways from KEGG. The ﬁrst factor (21.4% of
total variance) combined apoptosis with Jak-STAT path-
way and other immunity-related signaling (B-cell, T-cell,
toll-like receptor, and other pathways). Factor 2 explained
16.2% of the total variance. Unlike the ﬁrst analysis, ErbB
was placed with pathways MAPK, WNT, VEGF, insulin,
gonadotropin-releasing hormone, and calcium signaling.
The third factor (10.0%) conﬁrmed joint activity of PDGF,
IGF, and TGF-beta signaling, angiogenesis, and EMT
pathways. In addition, these were associated with tissue
growth pathways: adherens junction (KEGG04520), focal
adhesion (KEGG04510), regulation of actin cytoskeleton
(KEGG04810), and tight junction (KEGG04530).
Thus, by combining the cancer-related processes with
KEGG signaling pathways, we found that the former do
contribute signiﬁcantly to the factor structure of the sig-
naling pathways. We could see how the core cancer pro-
cesses cross-talk with their signaling counterparts in the
tumor transcriptome level.
Metabolicpathways
We previously observed that the signaling and metabolic
domains of the global gene interaction network are
poorly connected with each other (unpublished data). In
order to overview tumor functionality at the metabolic
level, we did factor analysis for 119 metabolic KEGG
pathways. Factor 1 (19.2% of total variance) was domi-
nated by metabolism of retinol, steroid hormones, ascor-
bate/aldarate, fatty acids and several amino acids. Fac-
tor 2 (10.6%) incorporated various pathways of sugar
metabolism and oxidative phosphorylation, while factor 3
(7.4%) combined metabolism of purine, pyrimidine, phos-
phonate/phosphinate, seleno-aminoacids, cysteine and
methionine.
Comparing the gene and protein expression data
Distinct AGSs from the transcriptomics and proteomics
data allowed a systematic analysis of both similarities and
diﬀerences between individual patients at molecular level.
For this we compared the NEA scores of individual AGSs
versus 264 FGSs for the two omics data; the plots are
given in the Additional ﬁle 1: Figure S2. Both manifested
higher mean scores for the ﬁve tissue growth-related
pathways: adherens junction (KEGG04520), gap junctionAlexeyenko etal. BMCBioinformatics 2012, 13:226 Page 10 of 11
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(KEGG04540), focal adhesion (KEGG04510), regulation
of actin cytoskeleton (KEGG04810), and tight junction
(KEGG04530). These pathways were highly enriched in
the vast majority of patients. Similarly, the score distribu-
tion of metabolic pathways was quite similar between the
two platforms in terms of means and variances. Intrigu-
ingly, the proteomics AGSs were strongly depleted in
cancer-related FGSs, whereas in the transcription domain
the cancer genesets showed the opposite pattern. We have
no explanation for this observation.
Conclusion
We have developed a network enrichment analysis that
can be considered a natural extension of the gene enrich-
ment analysis in the network context. NEA exploits the
richandgrowinginformationonthebiologicalinteraction
between genes at diﬀerent levels, including DNA, RNA
and protein, and from diﬀerent species. The statistical
power of this approach is higher than GEA, because the
number of potential connections between gene groups is
expandedfrom listed genesto alltheir network neighbors.
The analysis is robust if the gene network is suﬃciently
dense, so that only connections via several network links
between gene groups are considered. We provided such a
global gene network of functional coupling by integration
of high-throughput and literature data of [21], comple-
menting it with functional links from curated databases of
pathways, gene annotations, and protein complexes.
OurNEAmethodbydeﬁnitionisnotlimitedtoanysub-
networks or modules deﬁned by the network structure.
In comparison, NEA methods that analyze pre-deﬁned
network modules then perform GEA within each module
separately, and ignore all non-module genes. Algorithmic
solutions for identifying network modules are often con-
troversial, and might produce multiple solutions, where
each alternative is hard to validate. Furthermore, in our
experience with JActiveModules many identiﬁed modules
are either very small (fewer than 5 genes) or extremely
large,likelyrepresentingthelargestcomponentofthenet-
work, thus creating an additional level of uncertainty in
the analysis pipeline. This direction of research can be
extended beyond existing gene networks, e.g. attempting
to identify latent gene structures [29].
Genes, the members of FGS used in our analyses, often
overlap. This problem is common to all enrichment-
based methods that employ ready, third-party deﬁned
FGS. Solutions can include either resolving ambiguity
by rigorous weighted scoring [30] or creating curated,
non-overlapping FGS for speciﬁcally for enrichment anal-
yses, such as hallmarks of cancer, domains of enzymatic
activity, etc.
Obtaining the distribution of the network statistics
under the null hypothesis, which is needed for infer-
ence, is challenging, and we believe that this has hindered
network-based analyses so far. In this paper, we pro-
poseasequentialnetworkrandomizationalgorithm,using
the hypergeometric sampling model to obtain a fast pro-
cedure for large biological networks. Chen et al. [23]
proposed a sequential importance sampling method to
approximate the distribution of the statistics related to
the randomized 0-1 tables with ﬁxed margins. In contrast
to our procedure, they did not randomize the network
itself,butanapproximationtoitasdeterminedbythetrial
distribution. Hence, ﬁnding or constructing a good trial
distribution becomes an issue.
We have focused on the number of direct links with
equal weights as the key statistic, but some extensions
of this are worth pursuing. For example, one might con-
sider other network statistics, such as the number of
indirect links, or more generally, allow diﬀerent weights
for the links. In addition to analyzing an AGS in relation
to known gene sets, the NEA has a unique feature: it can
quantify the enrichment of single genes in the AGS. As
such an analysis does not require any prior gene group-
ing, it can be applied to all genes found in the network.
In this case the characterization of the AGS is based on
any available knowledge on the enriched individual genes,
such as gene description, presence of a certain protein
domain, etc.
Finally, in generating the randomized networks we have
constrained them only to have the have a speciﬁed degree
distribution. Let network assortativity be deﬁned as the
correlation between the degrees of the two nodes con-
nected by a link. In our randomized networks a large
node is more likely to be connected another large node
rather than to a small one. In other words the random-
ized networks tend to be assortative. The network that
we use has an assortativity of r = 0.2, indicating that
high-degree nodes are more frequently connected to high
degree nodes than to low-degree nodes. We observe the
same trend for the human STRING network [31] (link
conﬁdence cutoﬀ > 0.5, r = 0.32). This is opposite
to what was found by Newman [32] (r =− 0.15), and
Maslov and Sneppen [20] (r < 0). However, the networks
used in their studies were relatively small yeast networks
and purely based on physical protein interactions. In any
case, the impact of ignoring the second-order property on
network-based inferences requires further investigation.
Additional ﬁle
Additional ﬁle 1: Has three sections. Section A has two ﬁgures: In
Figure S1, we compared z-scores from GEA to those from MNEA and FNEA.
In Figure S2, we compared the NEA scores of individual AGSs versus 264
FGSs for the two omics data. Section B contains the list of pathways used in
our lung cancer study. Their meanings and references are also given. For
pedagogic purposes, in Section C, we provide a fully worked-out example
of analysis of lung cancer data from Bild etal.’s.Alexeyenko etal. BMCBioinformatics 2012, 13:226 Page 11 of 11
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